Skip to main content
SpringerLink
Log in

Diastolic Dysfuncion, Redox Stress, Extracellular Matrix Remodeling and Congestive Heart Failure in Diabetes Mellitus

  • Chapter
Frontiers in Cardiovascular Health

Part of the book series: Progress in Experimental Cardiology ((PREC,volume 9))

Summary

Congestive heart failure (CHF) is the one cardiovascular disease that has been increasing exponentially during the past decade. The current epidemic can only be expected to increase in the near future as our societies age. Hypertension (HTN), coronary artery disease (CAD), diabetes, and aging are currently the four big players and contribute to redox stress, myocellular and extramyocellular matrix (ECM) remodeling on the path to developing diastolic dysfunction (DD), systolic dysfunction (SD) and eventual CHF. The natural progression and history of CHF has a tendency to follow along two separate but interconnecting pathways as if tied together in a molecule. The roles of each of these factors will be discussed and the transition from DD to SD and overt CHF will be explored. Earlier diagnosis and compliance to current treatment paradigms by both the patient and physician are essential elements to slow or halt this progressive epidemic. Understanding the natural history of this morbid progressive disease will allow researchers and clinicians alike to develop novel treatment strategies and pave the way for newer developments in the diagnosis and treatment of CHF.

A part of this work was supported by NIU grants ML-71010 and ML-74185.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vasan RS, Levy D. 1996. The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med 156:1789–1796.

    Article  PubMed  CAS  Google Scholar 

  2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. 1996. The progression from hypertension to congestive heart failure. JAMA. May 275(20): 1604–1606.

    Article  Google Scholar 

  3. Remme WJ. 2000. Overview of the relationship between ischemia and congestive heart failure. Clin Cardiol. 23(7)(Suppl.IV):IV-4–IV-8.

    Google Scholar 

  4. American Heart Association. 1998. 1999 Heart and Stroke Statistical Update. American Heart Association. Dallas, Texas.

    Google Scholar 

  5. Gomberg-Maitland M, Baran DA, Fuster V 2001. Treatment of Congestive Heart Failure Guidelines for the primary care physician and the heart failure specialist. Arch Intern Med. Feb 161:342–352.

    Article  PubMed  CAS  Google Scholar 

  6. Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. 1994. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: The future rise of heart failure. Am J Public Health. 84:20–28.

    Article  PubMed  CAS  Google Scholar 

  7. Glasser SP. 2001. Hypertension syndrome and cardiovascular events: High blood pressure is only one risk factor. Postgraduate Medicine November 110(5):29–36.

    CAS  Google Scholar 

  8. Vasan RS, Larson MG, Benjamin EF, Evans JC, Reiss C, Levy D. 1999. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in population-based cohort. J Am Coll Cardiol. 33:1948–1955.

    Article  PubMed  CAS  Google Scholar 

  9. Mosterd A, Hoes AW, deBruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. 1999. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 20:447–455.

    Article  PubMed  CAS  Google Scholar 

  10. Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R. 1997. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 241: 387–394.

    Article  PubMed  CAS  Google Scholar 

  11. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. 1998. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 98:2282–2289.

    Article  PubMed  CAS  Google Scholar 

  12. Vasan RS, Levy D. 2000. Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation. 101 (17):2118–2126.

    Article  PubMed  CAS  Google Scholar 

  13. Weber KT. 1997. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation. 96:4065–4082.

    Article  PubMed  CAS  Google Scholar 

  14. Chatham JC, Forder JR, McNeill JH. 1996. The Heart in Diabetes. Kluwer Academic Publishers, Boston.

    Book  Google Scholar 

  15. Kannel WB, Hjortland, Castelli WP. 1974. Role of diabetes in congestive heart failure: The Framingham Study. Am J Cardiol 34:29.

    Article  PubMed  CAS  Google Scholar 

  16. Sowers JR, Epstein M. 1995. Diabetes mellitus and associated hypertension, vascular disease, and Nephropathy. Hypertension 26:869–879.

    Article  PubMed  CAS  Google Scholar 

  17. Sowers JR, Epstein M, Frohlich ED. 2001. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension Apr 37(4):1053–1059.

    Article  CAS  Google Scholar 

  18. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. 2001. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol Feb 1;87(3):320–323

    Article  CAS  Google Scholar 

  19. Griendling KK, Sorescu D. Masuko U-F. 2000. NAD(P)H Oxidase Role in cardiovascular biology and disease. Circulation Research 86(5):494.

    Article  PubMed  CAS  Google Scholar 

  20. Babior BM. 1999. NADPH oxidase: an update. Blood 93(5): 1464–1476.

    PubMed  CAS  Google Scholar 

  21. McCord JM, Fridovich I. 1988. Superoxide dismutase: the first twenty years (1968–1988). Free Radie Biol Med 5(5–6):363–369.

    Article  CAS  Google Scholar 

  22. Roos D, Weening RS, Wyss SR, Aebi HE. 1980. Protection of human neutrophils by endogenous catalase: Studies with cells from catalase-deficient individuals. J Clin Invest 65(6): 1515–1522.

    Article  PubMed  CAS  Google Scholar 

  23. Lawrence RA, Burk RF. 1978. Species, tissue and subcellular distribution of selenium dependent, glutathione peroxidase activity. J Nutr 108(6):981–987.

    PubMed  CAS  Google Scholar 

  24. Tyagi SC, Ratajska A, Weber KT. 1993. Myocardial matrix metalloproteinases: Localization and activation. Mol Cell Biochem. 126:49–59.

    Article  PubMed  CAS  Google Scholar 

  25. 25. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 98:2572–2579.

    Article  PubMed  CAS  Google Scholar 

  26. Lefer DJ, Granger DN. 2000. Oxidative stress and cardiac disease. Am J Med Sep 109(4):315–323.

    Article  CAS  Google Scholar 

  27. Dhalla NS, Elmoselhi AB, Hata T, Makino N. 2000. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res Aug 18;47(3):446–456.

    Article  CAS  Google Scholar 

  28. Sigusch HH, Campbell SE, Weber KT. 1996. Angiotensin II-induced myocardial fibrosis in rats: Role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res 31:546–554.

    PubMed  CAS  Google Scholar 

  29. Booz GW, Baker KM. 1995. Molecular signaling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 30:537–543.

    PubMed  CAS  Google Scholar 

  30. Kolpakov V, Gordon D, Kulik TJ. 1995. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cell. Circ Res 76:305–309.

    Article  PubMed  CAS  Google Scholar 

  31. Hingtgen SD, Davisson RL. 2001. Gene therapeutic approaches to oxidative stress-induced cardiac disease: principles, progress, and prospects. Antiox Redox Signal Jun 3(3):433–449

    Article  CAS  Google Scholar 

  32. Tyagi SC. 1999. Homocyst(e)ine and heart disease: Pathophysiology of extracellular matrix. Clin and Exper Hypertension 21 (3): 181–198.

    Article  CAS  Google Scholar 

  33. Mujumdar VS, Hayden MR, Tyagi SC. 2000. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. Journal of Cellular Physiology 183:28–36.

    Article  PubMed  CAS  Google Scholar 

  34. Meredith JE Jr., Fazeli B, Schwartz MA. 1993. The extracellular matrix as a cell survival factor. Mol Biol Cell 4(9):953–961.

    PubMed  CAS  Google Scholar 

  35. Rossi MA, Abreu MA, Santoro LB. 1998. Connective tissue skeleton of the human heart. A demonstration by cell-maceration scanning electron microscope method. Circulation 97:934–935.

    Article  PubMed  CAS  Google Scholar 

  36. Weber KT, Janicki JS, Pick R. Disruption of collagen tethers: Anatomic basis of muscle fiber slippage in the myocardium. Pages 18–35.

    Google Scholar 

  37. Jacob Seipel Zucker: Cardiac Dilatation. Gustav Fischer Verlag. Stuttgart. New York. 1990.

    Google Scholar 

  38. Weber KT. 1997. Extracellular matrix remodeling in heart failure: A role for De Novo angiotensin II generation. Circulation 96:4065–4082.

    Article  PubMed  CAS  Google Scholar 

  39. Francis GS. 1998. Changing the remodeling process in heart failure: basic mechanisms and laboratory results. Curr Opin Cardiol 13(3): 156–161.

    PubMed  CAS  Google Scholar 

  40. Weber KT. 2001. Aldosterone in congestive heart failure. Dec 345:1689–1697.

    Google Scholar 

  41. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7–22.

    Article  Google Scholar 

  42. Zannad F, Alla F, Dousset B, Perez A, Pitt B, RALES Investigators. 2000. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000; 102: 2700–2706. [Erratum, Circulation 2001; 103:476.

    Article  PubMed  CAS  Google Scholar 

  43. Cohn JN, Bristow MR, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. 1997. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart failure Research. Circulation. 95:766–770.

    Article  PubMed  CAS  Google Scholar 

  44. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B, Kajstura J, Leri A, Anversa P. 2002. Chimerism of the transplanted Heart. NEJM January 3 346(1):5–15.

    Article  Google Scholar 

  45. Li H, Simon H, Bocan TM, Peterson JT 2000. MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE-and MMP-inhibition. Cardiovasc Res 46(2):298–306.

    Article  PubMed  CAS  Google Scholar 

  46. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, Trail PA. 2001. Inhibition of angiogenesis and Metastasis in two murine models by the matrix metalloproteinases inhibitor, BMS-275291. Cancer Res 61(23):8480–8485.

    PubMed  CAS  Google Scholar 

  47. Vesely DL. 1999. Atrial natriuretic peptides in the diagnosis and treatment of congestive heart failure. Congestive Heart Failure 5:171–179.

    PubMed  CAS  Google Scholar 

  48. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B,Turi ZG, Hess OM. 2001. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. Nov 345(22): 1593–1600.

    Google Scholar 

  49. Homocysteine: The new risk factor: Introduction of patient management. March 1999; Professional Postgraduate Services ® (PPS), a division of Physicians World Communications Group, 400 Plaza Drive, Secaucus, NJ 07094.

    Google Scholar 

  50. Banas J. 1999. New insights into effects of statins on the atherosclerotic process. Cardiology Review Dec 16(12) (Suppl):1–4.

    Google Scholar 

  51. Takemoto M, Liao JK. 2001. Pleiotropic Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arteriosclerosis Thrombosis and Vascular Biology. Nov 21:1712–1719.

    Google Scholar 

  52. Hayden MR, Tyagi SC. 2001. “A” is for amylin and amyloid in type 2 diabetes mellitus. JOP J Pancreas (Online) 2(4):124–139. http://wunv.joplink.net

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of cardiovascular atherosclerosis metabolism and aging Camdenton Community Health Center, Camdenton, Missouri, USA, 65020

    M. R. Hayden

  2. FAHA., Deppartment of Physiology and Biophysics, The University of Mississippi Medical Center, Jackson, Mississippi, 39216-4505, USA

    Suresh C. Tyagi Ph. D.

  3. Department of Family and Community Medicine, University of Missouri-Columbia, MO, USA

    M. R. Hayden

Authors
  1. M. R. Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suresh C. Tyagi Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suresh C. Tyagi Ph. D. .

Editor information

Editors and Affiliations

  1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Naranjan S. Dhalla PhD, MD (Hon), DSc (Hon) (Distinguished Professor and Director), H. Ivan Berkowitz MBA (Consultant) & Pawan K. Singal PhD, DSc (Professor) (Distinguished Professor and Director),  (Consultant) &  (Professor)

  2. Institute of Circulatory & Respiratory Health, Canadian Institutes of Health Research, Vancouver, Canada

    Arun Chockalingam PhD (Assistant Director) (Assistant Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hayden, M.R., Tyagi, S.C. (2003). Diastolic Dysfuncion, Redox Stress, Extracellular Matrix Remodeling and Congestive Heart Failure in Diabetes Mellitus. In: Dhalla, N.S., Chockalingam, A., Berkowitz, H.I., Singal, P.K. (eds) Frontiers in Cardiovascular Health. Progress in Experimental Cardiology, vol 9. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0455-9_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0455-9_41

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5085-9

  • Online ISBN: 978-1-4615-0455-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation